The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?

Jun 18, 2020

During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, about the MANIFEST study. We asked: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis?

A number of preclinical studies have shown that the two agents work best in combination in murine models of MPN. Furthermore, results from the MANIFEST clinical trial suggest that CPI-0610 + ruxolitinib demonstrates superior clinical activity over the respective monotherapies.

MANIFEST study: Does the BET inhibitor CPI-0610 show synergy with ruxolitinib in MF?